Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter
Journal of Antimicrobial Chemotherapy, ISSN: 0305-7453, Vol: 63, Issue: 5, Page: 946-948
2009
- 43Citations
- 47Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations43
- Citation Indexes43
- 43
- CrossRef15
- Captures47
- Readers47
- 47
Article Description
Objectives: The aim of this study was to investigate the feasibility and efficacy of antisense-mediated gene silencing by peptide nucleic acid (PNA) for specific inactivation of the CmeABC multidrug efflux transporter in Campylobacter jejuni. Methods: PNA was designed to bind to the cmeA transcript and to inhibit the translation of CmeA, the periplasmic component of the RND-type CmeABC efflux transporter of C. jejuni. Inhibition of CmeA production was determined by western blotting. MICs of clinically important antibiotics, including ciprofloxacin and erythromycin, were measured in the presence of the CmeA-specific PNA (CmeA-PNA). Results: CmeA-PNA greatly reduced the expression level of CmeA. Consistent with the reduced CmeA production, CmeA-PNA rendered C. jejuni strains more susceptible to ciprofloxacin and erythromycin. At a concentration of 2 μM, CmeA-PNA resulted in 8- and 4-fold reductions in the MICs of ciprofloxacin and erythromycin, respectively, in C. jejuni NCTC 11168. CmeA-PNA also increased the susceptibility to the antibiotics in C. jejuni strains that were resistant to ciprofloxacin or erythromycin. Conclusions: Antisense technology is a feasible method to suppress the function of the CmeABC multidrug efflux transporter, which may be further exploited to control antibiotic-resistant Campylobacter. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=64649104323&origin=inward; http://dx.doi.org/10.1093/jac/dkp067; http://www.ncbi.nlm.nih.gov/pubmed/19279049; https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkp067; https://dx.doi.org/10.1093/jac/dkp067; https://academic.oup.com/jac/article-abstract/63/5/946/714768?redirectedFrom=fulltext
Oxford University Press (OUP)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know